Trump's drug tariff on Himachal Pharma, generic exports will survive; What did experts still say? - Solan Pharma - Industry incompetent by Trumps Tarif on General Medicine Know What the experts said

Updated: Fri, 26 Sep 2025 05:27 PM (IST) Tariff on drugs by US President Trump will have a limited impact on the Himachal Pradesh pharmaceutical industry, especially on generic drug manufacturers. Experts believe that most export is generic medicines that will not be rates. There may be some effects on brand medicine, but most industries will not be affected. The Baddi region, which is a Pharma hub, will remain an important center of generic medicine. Jagran correspondent, Solan. The decision of US President Donald Trump’s drug tariff will not affect the pharmaceutical industry of Himachal Pradesh, especially generic medicine. According to experts, this rate is mainly applied to brand medicine, while most medicines exported from India to the US fall into the generic category. In such a situation, Trump’s tariff plan has proven to be ineffective for the pharmaceutical world of Himachal. Remove ad just read the news, Rajesh Gupta, president of Himachal Pradesh Drug Manufacturing Association, believes that about 90 percent of the medicines exported from India to the US are generic. No rates are currently applied to this medicine. He said no official information was received from the US on the imposition of 100 percent rates. Even if it happens in the future, its effect will only be on brand medicine. According to Gupta, there are some industries in Himachal preparing brand medicine, but most of these businesses are also present in the US. In such a situation, the offer from there will continue at the local level and there will not have much impact on imports from India. He believes that only 10 percent of the industries will be affected by this tariff, while the remaining 90 percent will be safe. About 15 to 20 large industries produce generic medicine in Baddi-Barotiwala-Nalagarh (BBN) industrial area, also known as the country’s pharmaceutical center. These medicines of these industries are exported to the US as well as Europe, Africa and Asian countries. This is why Trump’s policy shows no major threat to the BBN industry. Industry representatives say that global demand for generic medicine is constantly increasing, this medicine is economical compared to brands and provides treatment to patients at affordable prices. The industrial city of India and especially Himachal Pradesh is an important center of generic production. About 35 percent of the total medicine prepared in India comes from Himachal Pradesh. Most of these medicines are produced by brands and generic, and this medicine is also exported in addition to India’s consumption. Medicines worth about 7,000 crore are exported from Himachal each year. Large industries such as Sun Pharmaceutical Industries Limited, Ranbaxy, Torrent Pharmaceuticals, Cipla, Indoco Pharma, Brux Laborators, Dr. Reddy, Lupine and Zidas Lifesains produce generic medicine in Baddi and Nalagarh in Himachal.